Annual Cash & Cash Equivalents
$43.05 M
-$22.42 M-34.24%
December 31, 2023
Summary
- As of March 12, 2025, ZVRA annual cash & cash equivalents is $43.05 million, with the most recent change of -$22.42 million (-34.24%) on December 31, 2023.
- During the last 3 years, ZVRA annual cash & cash equivalents has risen by +$38.84 million (+921.81%).
- ZVRA annual cash & cash equivalents is now -61.68% below its all-time high of $112.35 million, reached on December 31, 2021.
Performance
ZVRA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$54.04 M
+$14.78 M+37.64%
September 30, 2024
Summary
- As of March 12, 2025, ZVRA quarterly cash and cash equivalents is $54.04 million, with the most recent change of +$14.78 million (+37.64%) on September 30, 2024.
- Over the past year, ZVRA quarterly cash and cash equivalents has increased by +$10.99 million (+25.53%).
- ZVRA quarterly cash and cash equivalents is now -59.15% below its all-time high of $132.29 million, reached on June 1, 2021.
Performance
ZVRA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ZVRA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -34.2% | +25.5% |
| 3 y3 years | +921.8% | +25.5% |
| 5 y5 years | +133.8% | +25.5% |
ZVRA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -61.7% | at low | -46.1% | +37.6% |
| 5 y | 5-year | -61.7% | +1238.2% | -59.1% | +2193.7% |
| alltime | all time | -61.7% | +2086.8% | -59.1% | +2922.3% |
Zevra Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $54.04 M(+37.6%) |
| Jun 2024 | - | $39.26 M(-8.4%) |
| Mar 2024 | - | $42.85 M(-0.5%) |
| Dec 2023 | $43.05 M(-34.2%) | $43.05 M(-0.5%) |
| Sep 2023 | - | $43.27 M(-34.6%) |
| Jun 2023 | - | $66.20 M(+64.7%) |
| Mar 2023 | - | $40.18 M(-38.6%) |
| Dec 2022 | $65.47 M(-41.7%) | $65.47 M(-6.6%) |
| Sep 2022 | - | $70.06 M(-8.8%) |
| Jun 2022 | - | $76.78 M(-23.4%) |
| Mar 2022 | - | $100.24 M(-10.8%) |
| Dec 2021 | $112.35 M(+2566.7%) | - |
| Dec 2021 | - | $112.35 M(-14.6%) |
| Sep 2021 | - | $131.50 M(-0.6%) |
| Jun 2021 | - | $132.29 M(+74.3%) |
| Mar 2021 | - | $75.92 M(+1702.0%) |
| Dec 2020 | $4.21 M(+31.0%) | $4.21 M(-20.0%) |
| Sep 2020 | - | $5.27 M(-17.3%) |
| Jun 2020 | - | $6.37 M(+170.3%) |
| Mar 2020 | - | $2.36 M(-26.8%) |
| Dec 2019 | $3.22 M | $3.22 M(-50.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $6.52 M(-10.8%) |
| Jun 2019 | - | $7.31 M(-45.6%) |
| Mar 2019 | - | $13.44 M(-27.0%) |
| Dec 2018 | $18.41 M(+69.3%) | $18.41 M(+929.6%) |
| Sep 2018 | - | $1.79 M(-89.2%) |
| Jun 2018 | - | $16.50 M(+88.5%) |
| Mar 2018 | - | $8.75 M(-19.5%) |
| Dec 2017 | $10.87 M(-35.1%) | $10.87 M(+38.9%) |
| Sep 2017 | - | $7.83 M(-36.8%) |
| Jun 2017 | - | $12.39 M(-3.8%) |
| Mar 2017 | - | $12.88 M(-23.2%) |
| Dec 2016 | $16.76 M(-48.1%) | $16.76 M(-19.6%) |
| Sep 2016 | - | $20.85 M(-24.2%) |
| Jun 2016 | - | $27.51 M(-64.4%) |
| Mar 2016 | - | $77.33 M(+139.3%) |
| Dec 2015 | $32.32 M(+215.1%) | $32.32 M(-45.2%) |
| Sep 2015 | - | $59.01 M(-8.1%) |
| Jun 2015 | - | $64.22 M(+525.4%) |
| Mar 2015 | - | $10.27 M(+0.1%) |
| Dec 2014 | $10.26 M(+420.9%) | $10.26 M |
| Dec 2013 | $1.97 M | - |
FAQ
- What is Zevra Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Zevra Therapeutics?
- What is Zevra Therapeutics annual cash & cash equivalents year-on-year change?
- What is Zevra Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Zevra Therapeutics?
- What is Zevra Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Zevra Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ZVRA is $43.05 M
What is the all time high annual cash & cash equivalents for Zevra Therapeutics?
Zevra Therapeutics all-time high annual cash & cash equivalents is $112.35 M
What is Zevra Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ZVRA annual cash & cash equivalents has changed by -$22.42 M (-34.24%)
What is Zevra Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ZVRA is $54.04 M
What is the all time high quarterly cash and cash equivalents for Zevra Therapeutics?
Zevra Therapeutics all-time high quarterly cash and cash equivalents is $132.29 M
What is Zevra Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ZVRA quarterly cash and cash equivalents has changed by +$10.99 M (+25.53%)